Index RUT
P/E -
EPS (ttm) -0.30
Insider Own 3.86%
Shs Outstand 232.45M
Perf Week -2.02%
Market Cap 1.47B
Forward P/E 229.45
EPS next Y 0.03
Insider Trans -6.09%
Shs Float 223.70M
Perf Month -14.96%
Income -66.07M
PEG -
EPS next Q -0.15
Inst Own 59.68%
Short Float 15.17%
Perf Quarter -29.02%
Sales 124.46M
P/S 11.80
EPS this Y -48.52%
Inst Trans 51.39%
Short Ratio 6.13
Perf Half Y 66.93%
Book/sh 0.72
P/B 8.79
EPS next Y 106.17%
ROA -27.10%
Short Interest 33.93M
Perf Year 36.88%
Cash/sh 0.79
P/C 7.97
EPS next 5Y 30.00%
ROE -49.83%
52W Range 3.16 - 10.13
Perf YTD 1.77%
Dividend Est. -
P/FCF -
EPS past 5Y 28.61%
ROI -30.26%
52W High -37.71%
Beta 0.86
Dividend TTM -
Quick Ratio 4.64
Sales past 5Y 146.90%
Gross Margin 83.23%
52W Low 99.68%
ATR (14) 0.36
Dividend Ex-Date -
Current Ratio 4.88
EPS Y/Y TTM 37.17%
Oper. Margin -50.84%
RSI (14) 28.78
Volatility 4.37% 5.22%
Employees 267
Debt/Eq 0.34
Sales Y/Y TTM 138.61%
Profit Margin -53.08%
Recom 1.00
Target Price 13.44
Option/Short Yes / Yes
LT Debt/Eq 0.31
EPS Q/Q -324.64%
Payout -
Rel Volume 0.93
Prev Close 6.43
Sales Surprise 0.89%
EPS Surprise -26.72%
Sales Q/Q -22.22%
Earnings May 02 AMC
Avg Volume 5.53M
Price 6.31
SMA20 -9.75%
SMA50 -21.08%
SMA200 8.95%
Trades
Volume 5,167,715
Change -1.87%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Initiated
Leerink Partners
Outperform
$14
Dec-18-23 Initiated
Raymond James
Strong Buy
$12
Sep-07-23 Initiated
H.C. Wainwright
Buy
$9
Aug-25-23 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$5 → $10
Mar-03-23 Upgrade
Wedbush
Neutral → Outperform
$3 → $6
Nov-17-22 Upgrade
Piper Sandler
Neutral → Overweight
$3 → $8
May-06-22 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$7 → $1
Dec-01-21 Upgrade
Ladenburg Thalmann
Neutral → Buy
$6
Oct-14-21 Downgrade
Ladenburg Thalmann
Buy → Neutral
Jul-21-21 Downgrade
Jefferies
Buy → Hold
$11 → $2
Jul-20-21 Downgrade
Wedbush
Outperform → Neutral
$3
Jul-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$14 → $4
Mar-23-21 Initiated
Wedbush
Outperform
$14
Jan-06-21 Initiated
Cantor Fitzgerald
Overweight
$14
Oct-20-20 Resumed
Citigroup
Buy
$13
Feb-18-20 Resumed
Jefferies
Buy
$11
Feb-12-20 Initiated
Citigroup
Buy
$13
Feb-10-20 Initiated
Cowen
Outperform
Apr-08-19 Initiated
Piper Jaffray
Overweight
$15
Aug-24-18 Initiated
Jefferies
Buy
$7
Show Previous Ratings
Apr-25-24 10:02AM
Apr-18-24 08:00AM
Apr-02-24 11:34AM
Mar-28-24 04:05PM
Mar-25-24 08:00AM
06:00PM
Loading…
Mar-16-24 06:00PM
Mar-12-24 04:35PM
Feb-28-24 05:40PM
Feb-27-24 08:00AM
06:10AM
Feb-23-24 10:16AM
Feb-22-24 06:00PM
05:15PM
04:45PM
04:26PM
(Associated Press Finance)
04:01PM
Loading…
04:01PM
Feb-19-24 03:30PM
12:24PM
Feb-15-24 10:00AM
Feb-09-24 09:55AM
08:50AM
Feb-08-24 12:16PM
12:00PM
09:40AM
Feb-07-24 09:34AM
Feb-06-24 04:00PM
Feb-02-24 02:15AM
Feb-01-24 08:00AM
Jan-29-24 12:35PM
Jan-12-24 07:56AM
02:27PM
Loading…
Jan-10-24 02:27PM
Jan-08-24 08:00AM
Jan-03-24 08:03AM
Dec-29-23 11:01PM
Dec-20-23 08:00AM
Dec-14-23 06:40AM
Dec-05-23 09:11AM
Nov-21-23 04:02PM
09:37AM
08:01AM
Nov-17-23 09:00AM
Nov-15-23 04:02PM
Nov-13-23 04:02PM
Nov-10-23 08:05AM
Nov-06-23 08:00AM
Nov-03-23 08:00AM
Nov-02-23 09:40AM
Nov-01-23 10:42AM
Oct-31-23 11:15PM
(Thomson Reuters StreetEvents) +9.12%
05:09PM
08:40AM
07:29AM
(Associated Press Finance)
07:00AM
Oct-30-23 05:42PM
Oct-23-23 08:07AM
Oct-19-23 10:21AM
Oct-18-23 04:31PM
04:02PM
10:42AM
Oct-17-23 07:24PM
07:23PM
07:06PM
07:01PM
Oct-13-23 08:00AM
Oct-11-23 04:17PM
Oct-04-23 08:00AM
Sep-28-23 08:02AM
Sep-25-23 04:15AM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-11-23 08:00AM
Sep-08-23 08:00AM
Sep-07-23 08:00AM
Sep-06-23 12:36PM
12:13PM
Aug-30-23 01:02PM
Aug-28-23 10:22AM
Aug-26-23 03:17PM
Aug-25-23 09:42AM
Aug-24-23 11:05AM
Aug-17-23 09:31AM
Aug-07-23 02:34PM
Aug-04-23 08:29AM
Aug-03-23 08:26AM
Aug-02-23 08:35AM
07:26AM
07:00AM
Jul-27-23 04:05PM
Jul-26-23 07:55AM
Jul-20-23 04:05PM
Jul-16-23 09:37AM
Jul-13-23 08:00AM
Jun-29-23 04:09PM
Jun-19-23 08:00AM
Jun-08-23 09:48AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-23-23 04:05PM
May-22-23 03:30PM
May-17-23 07:30AM
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RAAB MICHAEL President & CEO Apr 15 '24 Sale 7.06 7,500 52,924 1,310,933 Apr 17 04:20 PM RAAB MICHAEL President & CEO Apr 01 '24 Sale 7.31 1,518 11,097 1,318,433 Apr 02 04:05 PM GRAMMER ELIZABETH A See Remarks Mar 20 '24 Sale 7.73 86,000 664,978 312,993 Mar 22 04:42 PM Rosenbaum David P. Chief Development Officer Feb 26 '24 Sale 9.20 5,183 47,684 175,936 Feb 28 06:57 PM RAAB MICHAEL President & CEO Feb 20 '24 Sale 8.75 22,917 200,439 1,319,951 Feb 22 04:58 PM Rodriguez Susan Chief Commercial Officer Feb 20 '24 Sale 8.75 6,928 60,594 452,795 Feb 22 04:56 PM Renz Justin A Chief Financial Officer Feb 20 '24 Sale 8.75 5,341 46,714 304,835 Feb 22 05:01 PM Blanks Robert See Remarks Feb 20 '24 Sale 8.75 5,017 43,880 368,186 Feb 22 04:58 PM Rosenbaum David P. Chief Development Officer Feb 20 '24 Sale 8.75 5,017 43,880 378,985 Feb 22 06:30 PM Williams Laura A Chief Medical Officer Feb 20 '24 Sale 8.75 4,803 42,008 380,138 Feb 22 04:56 PM GRAMMER ELIZABETH A See Remarks Feb 20 '24 Sale 8.75 4,432 38,764 398,993 Feb 22 04:57 PM Felsch Robert Ora See Remarks Feb 20 '24 Sale 8.75 2,352 20,571 184,834 Feb 22 04:56 PM Rosenbaum David P. Chief Development Officer Feb 20 '24 Sale 8.75 2,294 20,064 181,119 Feb 22 06:30 PM Rosenbaum David P. Chief Development Officer Feb 08 '24 Sale 9.18 15,344 140,846 384,002 Feb 09 04:14 PM Rosenbaum David P. Chief Development Officer Jan 08 '24 Sale 6.64 30,000 199,200 286,596 Jan 10 05:36 PM Renz Justin A Chief Financial Officer Dec 26 '23 Option Exercise 0.99 75,000 74,250 407,426 Dec 28 05:44 PM Renz Justin A Chief Financial Officer Dec 26 '23 Sale 6.36 225,000 1,430,122 182,426 Dec 28 05:44 PM Rosenbaum David P. Chief Development Officer Dec 18 '23 Sale 6.07 5,675 34,447 316,596 Dec 20 04:49 PM Rosenbaum David P. Chief Development Officer Dec 14 '23 Sale 5.55 7,000 38,850 322,271 Dec 15 06:13 PM GRAMMER ELIZABETH A See Remarks Dec 11 '23 Sale 5.08 50,000 253,925 275,675 Dec 13 05:44 PM Rosenbaum David P. Chief Development Officer Dec 08 '23 Sale 5.27 20,000 105,476 329,271 Dec 08 05:58 PM Rosenbaum David P. Chief Development Officer Dec 05 '23 Sale 5.00 10,272 51,360 349,271 Dec 06 04:49 PM Rosenbaum David P. Chief Development Officer Nov 30 '23 Sale 4.50 3,000 13,500 359,543 Dec 01 04:47 PM RAAB MICHAEL President & CEO Nov 20 '23 Sale 4.36 11,368 49,589 867,868 Nov 22 05:19 PM Rodriguez Susan Chief Commercial Officer Nov 20 '23 Sale 4.36 4,714 20,563 346,973 Nov 22 05:20 PM Renz Justin A Chief Financial Officer Nov 20 '23 Sale 4.36 2,873 12,533 332,426 Nov 22 05:20 PM Blanks Robert See Remarks Nov 20 '23 Sale 4.36 2,835 12,367 260,453 Nov 22 05:17 PM Rosenbaum David P. Chief Development Officer Nov 20 '23 Sale 4.36 2,835 12,367 362,543 Nov 22 05:21 PM Williams Laura A Chief Medical Officer Nov 20 '23 Sale 4.36 2,581 11,259 266,191 Nov 22 05:22 PM GRAMMER ELIZABETH A See Remarks Nov 20 '23 Sale 4.36 2,384 10,399 325,675 Nov 22 05:19 PM Felsch Robert Ora See Remarks Nov 20 '23 Sale 4.36 1,044 4,554 117,066 Nov 22 05:18 PM Rosenbaum David P. Chief Development Officer Nov 20 '23 Sale 4.36 932 4,066 113,293 Nov 22 05:21 PM Williams Laura A Chief Medical Officer Nov 15 '23 Sale 4.00 25,000 99,998 266,839 Nov 17 05:30 PM Rosenbaum David P. Chief Development Officer Oct 10 '23 Sale 4.00 1,644 6,576 365,378 Oct 12 05:09 PM Rosenbaum David P. Chief Development Officer Sep 08 '23 Sale 4.55 2,897 13,181 367,022 Sep 12 05:24 PM RAAB MICHAEL President & CEO Aug 21 '23 Sale 3.55 11,419 40,558 876,236 Aug 23 04:41 PM Rodriguez Susan Chief Commercial Officer Aug 21 '23 Sale 3.55 4,733 16,811 348,687 Aug 23 04:48 PM Renz Justin A Chief Financial Officer Aug 21 '23 Sale 3.55 2,884 10,243 333,849 Aug 23 04:42 PM Rosenbaum David P. Chief Development Officer Aug 21 '23 Sale 3.55 2,846 10,108 369,919 Aug 23 04:45 PM Blanks Robert See Remarks Aug 21 '23 Sale 3.55 2,846 10,108 263,288 Aug 23 04:36 PM Williams Laura A Chief Medical Officer Aug 21 '23 Sale 3.55 2,591 9,203 291,839 Aug 23 04:46 PM GRAMMER ELIZABETH A See Remarks Aug 21 '23 Sale 3.55 2,392 8,496 328,059 Aug 23 04:39 PM Felsch Robert Ora See Remarks Aug 21 '23 Sale 3.55 1,048 3,722 115,110 Aug 23 04:38 PM Rosenbaum David P. Chief Development Officer Aug 21 '23 Sale 3.55 937 3,328 111,225 Aug 23 04:45 PM Williams Laura A Chief Medical Officer Jun 27 '23 Sale 3.35 25,000 83,632 294,430 Jun 29 07:22 PM Blanks Robert See Remarks Jun 23 '23 Option Exercise 3.42 33,333 113,999 299,467 Jun 27 06:40 PM Blanks Robert See Remarks Jun 23 '23 Sale 3.63 33,333 121,042 266,134 Jun 27 06:40 PM RAAB MICHAEL President & CEO May 23 '23 Sale 3.65 11,357 41,489 887,655 May 25 08:55 AM Rodriguez Susan Chief Commercial Officer May 23 '23 Sale 3.65 4,711 17,210 353,420 May 25 08:52 AM Renz Justin A Chief Financial Officer May 23 '23 Sale 3.65 2,873 10,496 336,733 May 25 08:53 AM Blanks Robert See Remarks May 23 '23 Sale 3.65 2,835 10,357 266,134 May 25 08:54 AM Rosenbaum David P. Chief Development Officer May 23 '23 Sale 3.65 2,835 10,357 372,765 May 25 08:52 AM Williams Laura A Chief Medical Officer May 23 '23 Sale 3.65 2,583 9,436 319,430 May 25 08:51 AM GRAMMER ELIZABETH A See Remarks May 23 '23 Sale 3.65 2,384 8,709 330,451 May 25 08:54 AM Felsch Robert Ora See Remarks May 23 '23 Sale 3.65 1,046 3,821 116,158 May 25 08:55 AM Rosenbaum David P. Chief Development Officer May 23 '23 Sale 3.65 934 3,412 112,162 May 25 08:52 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite